Zymeworks Inc. (ZYME) fair value analysis
Nasdaq · Updated 2026-09-07
Zymeworks Inc. is a clinical-stage biopharmaceutical company that develops engineered therapeutics based on its Azymetric platform technology, which is designed to create improved antibody-based treatments for cancer and other diseases. The company is headquartered in Vancouver, Canada and operates in the United States and international markets.
Valuation status
Awaiting full valuationZYME does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $21.81
- Sector
- Healthcare
- 12-month range
- $16.94–$26.62
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The upper-middle quarter of its range
What our data shows for ZYME
- Shares are trading in the middle of their 12-month price range of $16.94–$26.62.
- The 14-day relative strength index sits at a neutral 64.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ZYME
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent ZYME news
TickrTrends' derived news-sentiment signal for ZYME is currently leaning positive, computed from recent coverage.
- Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval (seekingalpha.com, 2026-08-27)
TickrTrends take: Zymeworks' transition toward a royalty-driven model following Ziihera's approval represents a shift in the company's revenue structure that will be material to any future valuation assessment. As TickrTrends awaits full valuation metrics, investors should monitor how the company's cash flow composition changes as it moves from development-stage spending toward royalty income, since this fundamental business model transition will inform what valuation multiples are most relevant for comparison. The timing and magnitude of royalty revenue streams will be critical data points for establishing a defensible valuation in the Healthcare sector. - ZYME Looks 47.1% Overvalued on GF Value™ (gurufocus.com, 2026-08-26)
TickrTrends take: Zymeworks Inc. operates in the Healthcare sector and currently awaits a full valuation determination from TickrTrends. A valuation-focused reader monitoring ZYME should consider that overvaluation signals from fundamental analysis tools warrant attention to whether the company's financial metrics and growth prospects can justify its current market price. The pending comprehensive valuation assessment will be relevant for investors seeking clarity on ZYME's intrinsic value relative to its trading level. - ZYME Maintains Buy Rating by Citigroup -- Price Target Raised to $38 (gurufocus.com, 2026-08-26)
TickrTrends take: Citigroup's maintained buy rating and raised price target of $38 for ZYME suggests analyst confidence in the company's prospects, though TickrTrends is currently awaiting full valuation data on the Healthcare sector company. For valuation-focused investors, the divergence between Citigroup's $38 target and ZYME's current trading price would be a key metric to monitor as additional valuation metrics become available through TickrTrends. The timing of this analyst action may provide useful context once comprehensive valuation analysis is complete.
What people are saying
Follow the ZYME conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ZYME stock undervalued?
ZYME does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is ZYME's TickrTrends verdict?
ZYME is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is ZYME overbought or oversold?
ZYME's 14-day RSI is in neutral territory - neither overbought nor oversold.